(Bloomberg) The Food and Drug Administration’s staff raised concerns about safety data on a potential gene-editing treatment for sickle cell disease, ahead of a closely watched meeting where scientific experts will weigh the first therapy using Crispr technology. Most Read from BloombergHouse Speaker Mike Johnson’s First Big Bill Cuts Biden’s Climate Change FundingUS Military Attacks Two Syrian Facilities It Says Linked to IranIsrael Latest: US Strikes Two Iran-Linked Facilities in SyriaChina
The only cure for painful sickle cell disease today is a bone marrow transplant. On Tuesday, advisers to the Food and Drug Administration will review a gene therapy for the inherited blood disorder, which in the U.S. mostly affects Black people. If approved by the FDA, it would be the first gene therapy on the U.S. market based on CRISPR, the gene editing tool that won its inventors the Nobel Prize in 2020.